Literature DB >> 22981674

In-hospital mortality and failure to rescue after cytoreductive nephrectomy.

Quoc-Dien Trinh1, Marco Bianchi, Jens Hansen, Zhe Tian, Firas Abdollah, Shahrokh F Shariat, Francesco Montorsi, Paul Perrotte, Pierre I Karakiewicz, Maxine Sun.   

Abstract

BACKGROUND: The risk of in-hospital mortality after cytoreductive nephrectomy (CNT) is non-negligible and may vary widely according to various patient and hospital characteristics and clinical contexts.
OBJECTIVE: To better elucidate the mechanisms underlying variability in operative mortality after CNT. DESIGN, SETTING, AND PATIENTS: Using the US-based Nationwide Inpatient Sample registry, a weighted estimate of 16 285 patients with metastatic renal cell carcinoma (mRCC) treated with CNT between 1998 and 2007 was made retrospectively. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Failure to rescue (FTR), defined as the number of deaths in patients who developed an adverse outcome during hospitalization. Univariable and multivariable logistic regression models were used.
RESULTS: Of all 16 285 mRCC patients who underwent a CNT, 31% had an occurrence of one complication or more. The overall FTR rate was 5% and differed significantly according to age (≥ 75 yr vs <75 yr: 7.9% vs 4.3%) and comorbidities (≥ 3 vs 0: 7.7% vs 4.8%), as well as hospital bed size (small vs large: 7.2% vs 5.3%, all p ≤ 0.03). Patients who had an occurrence of infections (19.3%), cardiac- (15.7%), respiratory- (11.4%), or vascular-related complications (16.5%) had significantly higher FTR rates. It is noteworthy that increasing hospital volume and number of hospital beds also corresponded to lower rates of FTR after adjusting for other covariates.
CONCLUSIONS: Following CNT for mRCC, the occurrence of infections, cardiac-, respiratory-, or vascular-related complications resulted in higher FTR rates. Hospitals with greater number of beds and higher annual hospital volume had lower FTR rates, confirming the concepts that support FTR as an indicator for better quality of care following a high-risk surgical procedure. Crown
Copyright © 2012. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22981674     DOI: 10.1016/j.eururo.2012.08.069

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  12 in total

1.  Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.

Authors:  Shreyas S Joshi; Elizabeth A Handorf; Matthew Zibelman; Elizabeth R Plimack; Robert G Uzzo; Alexander Kutikov; Marc C Smaldone; Daniel M Geynisman
Journal:  Eur Urol       Date:  2018-06-05       Impact factor: 20.096

2.  Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.

Authors:  Nawar Hanna; Maxine Sun; Christian P Meyer; Paul L Nguyen; Sumanta K Pal; Steven L Chang; Guillermo de Velasco; Quoc-Dien Trinh; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

Review 3.  Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma.

Authors:  Walter R Hsiang; Patrick A Kenney; Michael S Leapman
Journal:  Curr Oncol Rep       Date:  2020-03-13       Impact factor: 5.075

Review 4.  Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review.

Authors:  Oscar Rodriguez Faba; Sabine D Brookman-May; Estefania Linares; Alberto Breda; Francesca Pisano; José Daniel Subiela; Francesco Sanguedolce; Maurizio Brausi; Joan Palou
Journal:  World J Urol       Date:  2017-07-12       Impact factor: 4.226

Review 5.  Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate?

Authors:  Roser Vives Dilme; Juan Gómez Rivas; Riccardo Campi; Javier Puente; Tamara Jerez; Dmitry Enikeev; Francesco Esperto; Jesús Moreno Sierra
Journal:  Curr Urol Rep       Date:  2021-10-16       Impact factor: 3.092

Review 6.  Current Status of Minimally Invasive Surgery for Renal Cell Carcinoma.

Authors:  Zachary L Smith
Journal:  Curr Urol Rep       Date:  2016-06       Impact factor: 3.092

Review 7.  Surgical management of renal cell carcinoma.

Authors:  Laura-Maria Krabbe; Aditya Bagrodia; Vitaly Margulis; Christopher G Wood
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

8.  Failure to rescue after major gynecologic surgery.

Authors:  Jason D Wright; Cande V Ananth; Laureen Ojalvo; Thomas J Herzog; Sharyn N Lewin; Yu-Shiang Lu; Alfred I Neugut; Dawn L Hershman
Journal:  Am J Obstet Gynecol       Date:  2013-08-09       Impact factor: 8.661

9.  Trends and variations in the rates of hospital complications, failure-to-rescue and 30-day mortality in surgical patients in New South Wales, Australia, 2002-2009.

Authors:  Lixin Ou; Jack Chen; Hassan Assareh; Stephanie J Hollis; Ken Hillman; Arthas Flabouris
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

Review 10.  Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.

Authors:  Brian M Shinder; Kevin Rhee; Douglas Farrell; Nicholas J Farber; Mark N Stein; Thomas L Jang; Eric A Singer
Journal:  Front Oncol       Date:  2017-05-31       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.